Recombinant adeno-associated viral (AAV) vectors are one of the most promising therapeutic delivery systems for gene therapy to the central nervous system (CNS). Preclinical testing of novel gene therapies requires the careful design and production of AAV vectors and their successful application in a model of CNS injury. One major limitation of AAV vectors is their limited packaging capacity (<5 kb) making the co-expression of two genes (e.g., from two promoters) diffi cult. An internal ribosomal entry site has been used to express two genes: However, the second transgene is often expressed at lower levels than the fi rst. In addition to this, achieving high levels of transduction in the CNS can be challenging. In this chapter we describe the cloning of a bicistronic AAV vector that uses the foot-and-mouth disease virus 2A sequence to effi ciently express two genes from a single promoter. Bicistronic expression of a therapeutic gene and a reporter gene is desirable so that the axons from transduced neurons can be tracked and, after CNS injury, the amount of axonal sprouting or regeneration quantifi ed. We go on to describe how to perform a pyramidotomy model of CNS injury and the injection of AAV vectors into the sensorimotor cortex to provide effi cient transduction and bicistronic gene expression in cortical neurons such that transduced axons are detectable in the dorsal columns of the spinal cord.
Introduction
Following an injury to the central nervous system (CNS) neurons undergo collateral sprouting but very limited long-distance regeneration which results in their failure to form functional connections with their original targets. This is due in part to the reduced intrinsic growth state of mature CNS neurons, which is characterized by their failure to express regeneration-associated genes (RAGs) after an injury [ 1 -5 ] . Steady advancements in molecular neurobiology have elevated gene therapy into a promising therapeutic strategy for increasing the expression of RAGs and improving regeneration after a CNS injury [ 6 -9 ] .
To test a potential gene therapy an in vivo model of CNS injury is required. The corticospinal tract (CST) is present in all mammals and originates from the pyramidal corticospinal neurons (CSNs) in layer V of the cerebral cortex that project axons through the brainstem to the spinal cord. The CST fi bers descend through the ventral brainstem in the medullary pyramids after which the main component of the CST decussates at the spinomedullary junction to form the dorsal CST which runs in the ventral portion of the contralateral dorsal funiculus in the adult rat [ 10 ] . The CST is a descending motor pathway that primarily controls locomotion, posture, and voluntary skilled movements [ 11 ] . Following injury to the rodent CST, persistent defi cits in sensorimotor function are observed and restorative strategies are often assessed using behavioural tests of sensorimotor and skilled motor function [ 11 -14 ] . The CST can be lesioned by performing a unilateral pyramidotomy (i.e., one of the medullary pyramids is cut) [ 15 ] . This leads to the anterograde degeneration of the injured axons and functional deficits on the contralateral side of the body. These defi cits can be overcome by enhancing the growth state of the uninjured CSNs, allowing them to sprout their axons across the midline and reinnervate the area denervated by the lesion. The pyramidotomy model has been extensively used to assess potential therapies to enhance neuronal regeneration and sprouting and functional recovery following CNS injury [ 8 , 16 ] . However, effi cient, widespread transduction of the CSNs in the cortex is challenging and has only been achieved when high titers (1 × 10 14 genome copies (GC)/mL) and slow infusion rates were used [ 6 , 8 , 17 ] . Here we outline a procedure to inject AAV vectors into the cortex to transduce CSNs and then perform a pyramidotomy injury.
Recombinant adeno-associated viral (AAV) vectors represent one of the most attractive gene delivery systems for the CNS due to their ability to effi ciently transduce neurons and to provide long-term expression with only a minimal immune response [ 18 , 19 ] . AAV vectors have one of the best characterized safety profi les and have been taken to clinical trial for a number of neurodegenerative diseases [ 20 , 21 ] . In addition to this, Glybera (an AAV vector encoding lipoprotein lipase) has recently been approved for use in the EU to reduce the incidence of pancreatitis in people with inherited lipoprotein lipase defi ciency [ 22 ] and paves the way for further AAV-based gene therapies for other conditions. Each AAV serotype expresses different capsid proteins that determine which receptors the AAV vector can bind to for cell entry and therefore establishes the AAV vector's tropism [ 23 ] . Pseudotyping AAV2 genome with the capsid from different AAV serotypes can generate vectors with different tissue and cellular tropisms, which can improve the effi ciency and pattern of transduction in specifi c regions of the CNS [ 24 -26 ] . We have previously shown that AAV1 is the optimal serotype for transducing CSNs in adult rats [ 17 ] although other AAVs also work well: AAV5 [ 27 -29 ] and AAV8 [ 6 , 28 , 30 ] . Viral vector-mediated over-expression of pro-regenerative genes, including retinoic acid receptor, beta (RARbeta2), neuronal calcium sensor 1 (NCS1), and Kruppel-like factor 7 (KLF-7), have been shown to enhance the intrinsic growth state of CSNs and facilitate axonal regeneration after injury [ 6 -9 ] . However, these studies have either used viral vectors with larger insert capacities such as lentiviral vectors or used two separate AAV vectors: one encoding a RAG and the other a reporter gene. It would therefore be very valuable to have an AAV vectors which can co-express a pro-regenerative gene together with a fl uorescent reporter so that transduced axons can be distinguished from axons that are not transduced: this would increase our ability to identify useful proregenerative therapies.
A disadvantage of AAV vectors is their relatively low insert capacity which can be an issue if two genes are required to be expressed (e.g., from two promoters) . One partial solution is to use a single promoter which drives two genes linked by an internal ribosomal entry site (IRES) [ 31 , 32 ] : typically, the RAG would be expressed immediately downstream of the promoter, whilst the fl uorescent reporter gene is expressed downstream of the IRES. Although this works reasonably well, the IRES-dependent second gene is usually expressed at a signifi cantly lower level, estimated at tenfold less than the cap-dependent fi rst gene [ 33 , 34 ] . To date we know of no reports where transduction of supraspinal neuronal cell bodies with such an AAV vector results in detectable labelling of their axons in the spinal cord.
This problem can be mitigated by using the 2A peptide from the foot-and-mouth disease virus (FMDV) [ 35 ] . The 2A peptide sequence is only 24 amino acids long and can mediate effi cient bicistronic expression of two gene products from a single promoter by undergoing ribosomal skipping (referred to as "self-cleavage") during protein translation. Theoretically, the two gene products are expressed in a 1:1 ratio, and in practice each gene product is expressed at a high level. The 2A and 2A-like bicistronic systems have been shown to be highly effective in the CNS where high expression levels of both genes have been demonstrated [ 6 , 34 ] .
Materials
Plasmids : The psubCMV-2A-WPRE plasmid (Fig. 1a ) was a kind gift from Dr. Hansruedi Bueler, University of Kentucky. The plasmid contains a cytomegalovirus (CMV) promoter (to drive expression of the bicistron), the FMDV 2A sequence, and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). The 2A sequence is immediately fl anked by an upstream (i.e., 5′)
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NheI restriction site and a downstream (i.e., 3′) MluI restriction site (Fig. 1b ) , see Note 1.
Enzymes : NheI and MluI, NEBuffer 4, and BSA (NEB, UK). Alkaline phosphatase (calf intestinal) (NEB, UK).
PCR reagents : Vent DNA polymerase (NEB, UK), 10× Vent DNA polymerase buffer, DMSO, 10 mM Nucleotide mix (Promega, UK), 100 mM MgSO 4 , 100 μM forward and reverse primers, 50 ng plasmids containing mCherry or EGFP, PCR-grade nucleotide-free H 2 O. Anaesthetic : 0.5 mg/kg Domitor (medetomidine hydrochloride) and 100 mg/kg Vetalar (ketamine hydrochloride) or with a mixture of isofl urane (1.5 %) and O 2 (1 L/min).
Analgesia : 5 mg/kg Carprofen was administered subcutaneously for postoperative analgesia.
Euthanasia solutions : 400 mg/kg Lethabarb (sodium pento barbital).
Our goal was to generate a series of plasmids with the generic structure (AAV-RAG-2A-EGFP). First, we cloned EGFP downstream of 2A, and then we cloned mCherry upstream of 2A. The resulting plasmid (AAV-mCherry-2A-EGFP-WPRE) (Fig. 1c ) has been used in many of our experiments as a negative control Forward and reverse primers were designed for EGFP (Fig. 4 ) and mCherry ( Fig. 5 ) to ensure that the coding region of the plasmid produced one single open reading frame encoding all of the following: a start codon, the upstream cDNA (mCherry in this case), the 2A sequence, and the downstream cDNA (EGFP in this case), and a stop codon.
Cloning Strategy and Primer Design
For cloning EGFP downstream of the 2A sequence, the forward primer was designed to contain a hexamer of GC repeats (blue) for stability of the PCR product and effi cient restriction enzyme cleavage, an MluI restriction site (yellow), and the fi rst For cloning mCherry upstream of the 2A, the forward primer was designed to contain a hexamer of GC repeats (blue) for stability of the PCR product and effi cient restriction enzyme cleavage, a NheI restriction site (pink), and the fi rst 28 bases of the mCherry ( a ) Western blotting of 10 μg of protein lysate using an anti-mCherry antibody (Abcam-ab167453) detected a band at the expected size for mCherry protein (~30 kDa) and was a similar size as our mCherry-positive control (mCherry expressed from a monocistronic plasmid). The mCherry protein from the 2A plasmid was at a slightly larger molecular weight than the control mCherry protein which was expected due to the addition of 23 amino acids at its C-terminus following "self-cleavage" of the 2A sequence . Only a very faint band was detected at ~60 kDa, as would occur if an mCherry-2A-EGFP fusion protein was produced, demonstrating effi cient 2A "self-cleavage" of the two proteins. Several unidentifi ed bands were detected at smaller molecular weights for both the 2A plasmid and the mCherry-positive control. ( b ) We were unable to detect EGFP protein expression from the 2A plasmid via western blotting using several different anti-EGFP antibodies (Lifespan Bioscience-C183899, Clontech-632569, Abcam-ab13970, Sigma-G1546). However we did detect a band at the correct size for EGFP (~30 kDa) in our EGFP-positive control (EGFP expressed from a monocistronic plasmid) cDNA (red) including the start codon (ATG; bold and underlined). The reverse primer contained the GC repeat hexamer (blue), a NheI restriction site (pink), and the reverse complement of the last 28 bases of the mCherry cDNA with the stop codon excluded (red).
Primers were synthesized at 50 nmol with desalting but no other purifi cation (Sigma, UK). We always check the resulting AAV plasmids by DNA sequencing to ensure that sequences are correct.
Sequencing primer used to check the success of cloning a gene upstream of 2A:
Sequencing primer used to check the success of cloning a gene downstream of 2A:
The reagents included in our standard PCR were as follows:
Volume (μL)
Final concentration Brain atlas for stereotaxic coordinates : Holes were drilled through the skull above the sensorimotor cortex using coordinates reported in a microstimulation mapping study relative to bregma, midline, and the brain surface [ 36 , 37 ] ( see Subheading 3 for coordinates). 2. An aliquot of the amplicons (2.5 μL of the 100 μL reaction) was analyzed using agarose gel electrophoresis to ensure that the PCR products were of the expected sizes.
3. These blunt-ended amplicons were separately cloned into the pCR-BluntII-TOPO plasmid (Invitrogen, UK) according to the manufacturer's instructions, creating pCR-BluntII-TOPOmCherry and pCR-BluntII-TOPO-EGFP. Competent E. coli were then transformed using the heat-shock protocol and 3 μL of the cloning reaction. Transformants were streaked out onto LB-agar plates containing kanamycin (10 μg/mL).
4.
A day later, putative positive clones were inoculated into 5 mL of LB-kanamycin and DNA was purifi ed using standard minipreps (Promega, UK).
5. Clones were screened by restriction digests of the purifi ed DNA using 0.5-1.0 μg of pCR-BluntII-TOPO-mCherry or pCR-BluntII-TOPO-EGFP digested by NheI or MluI, respectively. Our standard screening restriction digests were as follows, see 6. Clones were screened by performing an MluI or an NheI restriction digest and visualized using agarose gel electrophoresis to ensure that the cDNA inserts were present. Subsequently,
Plasmid Design and Cloning
these clones were sequenced using the SP6 and T7 primer sites that fl ank the "multiple cloning site" of pCR-Blunt II-TOPO to ensure the fi delity of the PCR amplifi cation.
7. At least 10 μg of the psub-CMV-2A-WPRE vector was digested with MluI and then treated with alkaline phosphatase to prevent re-circularization. Similarly, 10 μg of pCR-BluntII-TOPO-EGFP was also digested with MluI to release the EGFP cDNA. Both the vector (Fig. 6 , lane 1) and the insert (Fig. 6 , lane 2) were then purifi ed using gel extraction.
8. The EGFP cDNA insert was then ligated into the vector using T4 DNA ligase, following the manufacturer's protocol, to create psub-CMV-2A-EGFP-WPRE.
9. This new plasmid was transformed into E. coli , and clones were screened for the presence of the insert using an MluI restriction digest (as described above) (Fig. 6 , lane 3) and then sequenced to ensure the correct orientation of the EGFP insert.
10. Next, to clone in mCherry upstream of the 2A-EGFP sequence, psub-CMV-2A-EGFP-WPRE was digested with NheI and treated with alkaline phosphatase. The pCR-BluntII-TOPOmCherry was also digested with NheI to release the mCherry cDNA. (Fig. 6 , lane 4) and the mCherry cDNA insert (Fig. 6 , lane 5) were gel purifi ed and then ligated using T4 DNA ligase to create psub-CMVmCherry-2A-EGFP-WPRE and transformed into E. coli . The following day, DNA minipreps were obtained for 10-20 colonies.
12. Clones were screened for the presence of the insert via NheI restriction digest (Fig. 6 , lane 6) and then sequenced to ensure the correct orientation of mCherry.
psub-CMV-mCherry-2A-EGFP-WPRE was digested with
MluI and NheI to show the presence of both EGFP and mCherry (Fig. 6 , lane 7) .
14. psub-CMV-mCherry-2A-EGFP-WPRE was digested with XhoI to illustrate the increased size of the linearized plasmid (Fig. 6 , lane 8) relative to lanes 1 and 4.
1. Because it is expensive to generate AAV vectors, we routinely screen newly cloned AAV transfer plasmids in vitro using electroporation [ 38 ] . We can check that the plasmid is expressing the reporter protein (Fig. 2 ) , and, if the plasmid contains a RAG, that it promotes neurite outgrowth, see Note 8.
AAV vectors were generated by the Miami Project Viral Vector
Core using FPLC-based purifi cation.
2. The AAV vector transgene cassette was fl anked by noncoding inverted terminal repeats (ITRs), which were the only wildtype viral sequences present. The AAV vectors were pseudotyped with AAV capsid serotype 1. Following production, the AAV vectors were titered using quantitative PCR to determine the number of genomic copies and an infection assay on 293 T cells was conducted to verify transduction effi ciency.
1. Female adult Lister hooded rats (Charles River, UK) weighing 200-220 g were anesthetized with an intraperitoneal injection of 0.5 mg/kg Domitor (medetomidine hydrochloride) and 100 mg/kg Vetalar (ketamine hydrochloride).
2. Once anesthetized, the head was shaved and sterilized using chlorhexidine disinfectant.
3. Eye lubricant was applied to the eyes, and throughout the surgery, the animals' body temperature was maintained at 37 °C with a thermal heating blanket connected to a rectal temperature probe.
4. The rats' head was placed into the stereotaxic frame, and the incisor bar was lowered 2 mm below the horizontal plane so
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that the heights of lambda and bregma were equal and the surface of the skull was fl at (Fig. 7 ) .
5. Following a midline incision, the skin was retracted using small bulldog clamps and the periosteum was removed with a scalpel blade to expose the skull surface.
6. The microdrill was fi xed to the stereotaxic frame holder and the drill burr centred over bregma. Six holes were then drilled through the skull above the left or the right sensorimotor cortex using coordinates reported in a microstimulation mapping study relative to bregma, midline, and the brain surface (Fig. 7 ) . Defi ned as anterior-posterior (AP), medial-lateral (ML), and dorsal-ventral (DV): Second: 3.5 mm ML, +0.5 mm AP, DV −1.5 mm.
Third: 3.5 mm ML, +2 mm AP, DV −1.5 mm.
Fourth: 2.5 mm ML, +1.5 mm AP, DV −1.5 mm.
Fifth: 2.5 mm ML, +0.5 mm AP, DV −1.5 mm.
Sixth: 1.5 mm ML, +1 mm AP, DV −1.5 mm.
7. A 10 μL Hamilton syringe fi tted with a 15 mm, 34 gauge, small hub removable needle was loaded with 3 μL of viral vector and fi xed to the stereotaxic frame holder.
8. The tip of the needle was positioned over the fi rst hole and lowered onto the brain surface. Once on the brain surface it was lowered a further 1.5 mm into the sensorimotor cortex.
9. 0.5 μL of AAV vector was infused into the brain using a microsyringe pump. The infusion rate was set to 200 nL/min on the Micro4 control panel, see Note 9 .
10. Once the pump infusion was fi nished the needle was left in place for 3 min to allow the AAV vector to diffuse from the injection site.
11
. The needle was then removed and positioned at the second coordinate to inject the next 0.5 μL of AAV vector. This process was repeated until all six injections were complete.
12. After the last injection the skin was closed using 3.0 vicryl sutures.
13
. The rats were then placed into an incubator at 37 °C and 1 mg/kg Antisedan (atipamezole hydrochloride) was administered Subcutaneously. Once awake, 5 mg/kg Carprofen was administered subcutaneously for postoperative analgesia.
1. Rats were anesthetized using 5 % isofl urane in O 2 (fl ow rate 1.5 L/min) and maintained with 1-2 % isofl urane in O 2 . Throughout the surgery the animals' body temperature was maintained at 37 °C with a thermal heating blanket connected to a rectal temperature probe, see Note 10.
2. The ventral neck region was shaved and sterilized using chlorhexidine disinfectant.
3. A midline incision is made from the chin to the rostral end of the sternum and the outer layers of gland, and muscle tissue is blunt dissected until the trachea is exposed.
4. The trachea is displaced slightly to one side, and the underlying muscle is dissected rostrally until the basioccipital skull is reached, see Note 11 .
5. Surgical long-teethed retractors are inserted to allow access to the basioccipital bone.
Pyramidotomy Injury Model
6. A craniotomy of the ventral occipital bone was performed using a microdrill. This allows access to the medullary pyramids, which are located medially.
7. The left or the right pyramid was cut using Vannas microscissors making sure that the medial boundary close to the basilar artery is lesioned as well, see Notes 12 -14 .
8. Any bleeding is stopped, and the skin is sutured using 3.0 vicryl sutures.
9. The rats were placed in an incubator at 37 °C until fully awake. 5 mg/kg Carprofen was administered subcutaneously for postoperative analgesia.
1. 10 weeks post-injection, the rats were terminally anesthetized by intraperitoneal injection of 400 mg/kg Euthasol (sodium pentobarbital) and transcardially perfused with 200 mL PBS (pH 7.4) to remove the blood, followed by 200 mL 4 % paraformaldehyde in PBS (pH 7.4).
2. Immediately following perfusion the brain and spinal cord were dissected and post-fi xed in 4 % paraformaldehyde in PBS for 2 h at 4 °C. 5. Once the gelatin had set, they were placed overnight in 4 % paraformaldehyde in PBS at 4 °C to harden.
6. To allow tissue from each brain to undergo different immunohistological analysis the brains were cut rostro-caudally into 50 μm coronal serial sections using a freezing microtome and collected into ten series in a 24-well plate containing PBS and 0.1 % sodium azide. The spinal cords were cut rostro-caudally into 30 μm transverse serial sections and stored in the same manner.
7. The tissue sections were then mounted onto microscope slides using Mowiol and kept in the dark.
1. Slides were imaged using a confocal microscope (Fig. 8 ) . Unexpectedly, some fi bers in the dorsal columns appear to be just mCherry or EGFP positive. We are unsure why this is, but it may refl ect differences in the vesicular transport of the two proteins. Others have reported similar issues (Wall et al [ 39 ] and references therein). Moreover, we have not yet been able to detect transgene positive axon collaterals in the spinal grey matter Sigma-G1546) raised against different regions of the EGFP protein including the N-and C-terminus, and the C-terminus of the downstream gene should not be affected by "self-cleavage" of the 2A sequence.
Notes
3. Note that our intermediate plasmid (psub-CMV-2A-EGFP) will not express EGFP in vitro or in vivo unless a transgene (containing an appropriate start codon) is cloned upstream of 2A.
4. It is important to choose the correct AAV serotype for the cell type you wish to transduce. We and others have previously shown that AAV1 and 5 are the optimal serotypes for transducing cortical neurons.
5. Using high-titer AAV vectors is a crucial factor for achieving high-level transduction, ideally 1 × 10 13 GC/mL or higher.
6. The extension time of the PCR cycle was increased in instances where the cDNA was signifi cantly larger. Some of the RAGs we cloned were over 3,000 bp long and required an increase in the extension time to 6 min. 7. The cDNA to be inserted must be checked to ensure that none of the restriction sites used for cloning (MluI and NheI) are present within the coding region. For example one of our RAGs contained an NheI site within its coding sequence. We replaced the NheI restriction site of the upstream and downstream primers with an SpeI restriction site that has an identical overhang to NheI. However, a ligation of DNA products digested by NheI and SpeI loses the restriction site for both enzymes and it cannot be subsequently restriction digested by either enzyme.
8. Note that "self-cleavage" of the 2A plasmid results in the upstream gene product having an additional 23 amino acids attached to the C-terminus and the downstream gene product having one additional amino acid attached to the N-terminus (Fig. 1b) . The consequences of this additional sequence need to be verifi ed empirically on a case-by-case basis, but in our experience, most pro-regenerative genes continue to show pro-regenerative effects in vitro after being shuttled from a monocistronic plasmid into the bicistronic psub-CMV-2A-EGFP-WPRE plasmid.
9. An important step in achieving high levels of transduction and a large area of transduction is the use of a micropump to slowly inject the viral vector over several minutes. In addition once the injection is complete it is also important to leave the needle in place for at least a couple of minutes to allow viral vector diffusion away from the injection sites.
10. The pyramidotomy surgery requires practice. High mortality rates are associated with the pyramidotomy surgery ( see Steward et al. [ 40 ] and Kathe et al. [ 41 ] ).
11. Displacement of the trachea can cause breathing diffi culties or apnea. Giving Dopram (Dopram V-Drops, 20 mg/mL), a respiratory stimulant, during the surgery can increase breathing activity. Furthermore, loosening of the retractors multiple times during the surgery can stabilize the animal.
12. When the pyramids are lesioned the basilar artery should be avoided. In addition to this, if the cut is made too deep it can affect the midbrain nuclei that are part of the breathing and cardiovascular centers.
13. Lesions are often incomplete. Repeating the cut with a 26 G needle including the fi bers close to the basilar artery will prevent this to some extent.
14. Immunohistochemical staining for PKCγ can be used to verify completeness of the pyramidotomy lesion.
